<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:06:21Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8477868" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8477868</identifier>
        <datestamp>2021-10-01</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="jah36326" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8477868</article-id>
              <article-id pub-id-type="pmcid">PMC8477868</article-id>
              <article-id pub-id-type="pmc-uid">8477868</article-id>
              <article-id pub-id-type="pmid">34075778</article-id>
              <article-id pub-id-type="pmid">34075778</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.120.020865</article-id>
              <article-id pub-id-type="publisher-id">JAH36326</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Arrhythmia and Electrophysiology</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Low‐Level Tragus Stimulation Modulates Atrial Alternans and Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation</article-title>
                <alt-title alt-title-type="right-running-head">Tragus Stimulation Modulates Alternans During AF</alt-title>
                <alt-title alt-title-type="left-running-head">Kulkarni et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah36326-cr-0001" contrib-type="author">
                  <name>
                    <surname>Kulkarni</surname>
                    <given-names>Kanchan</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3185-0484</contrib-id>
                  <xref rid="jah36326-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah36326-cr-0002" contrib-type="author">
                  <name>
                    <surname>Singh</surname>
                    <given-names>Jagmeet P.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2724-529X</contrib-id>
                  <xref rid="jah36326-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah36326-cr-0003" contrib-type="author">
                  <name>
                    <surname>Parks</surname>
                    <given-names>Kimberly A.</given-names>
                  </name>
                  <degrees>DO</degrees>
                  <xref rid="jah36326-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah36326-cr-0004" contrib-type="author">
                  <name>
                    <surname>Katritsis</surname>
                    <given-names>Demosthenes G.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="jah36326-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jah36326-cr-0005" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Stavrakis</surname>
                    <given-names>Stavros</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4370-8135</contrib-id>
                  <xref rid="jah36326-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <address>
                    <email>Stavros-stavrakis@ouhsc.edu</email>
                  </address>
                </contrib>
                <contrib id="jah36326-cr-0006" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Armoundas</surname>
                    <given-names>Antonis A.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5006-1547</contrib-id>
                  <xref rid="jah36326-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah36326-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <address>
                    <email>armoundas.antonis@mgh.harvard.edu</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="jah36326-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Cardiovascular Research Center</named-content>
                <institution>Massachusetts General Hospital</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <aff id="jah36326-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Cardiology Division</named-content>
                <named-content content-type="organisation-division">Cardiac Arrhythmia Service</named-content>
                <institution>Massachusetts General Hospital</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <aff id="jah36326-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Cardiology Division</named-content>
                <institution>Brigham and Womens Hospital</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <aff id="jah36326-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <institution>Hygeia Hospital</institution>
                <city>Athens</city>
                <country country="GR">Greece</country>
              </aff>
              <aff id="jah36326-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Heart Rhythm Institute</named-content>
                <institution>University of Oklahoma Health Sciences Center</institution>
                <city>Oklahoma City</city>
                <named-content content-type="country-part">OK</named-content>
              </aff>
              <aff id="jah36326-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Institute for Medical Engineering and Science</named-content>
                <institution>Massachusetts Institute of Technology</institution>
                <institution>Cambridge</institution>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Antonis A. Armoundas, PhD, Cardiovascular Research Center, Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129. E‐mail: <email>armoundas.antonis@mgh.harvard.edu</email>
<break/>and<break/> Stavros Stavrakis, MD, PhD, Heart Rhythm Institute, University of Oklahoma Health Sciences Ctr, 800 Stanton L Young Blvd, Suite 5400, Oklahoma City, OK 73104. E‐mail: <email>Stavros-stavrakis@ouhsc.edu</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>02</day>
                <month>6</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>15</day>
                <month>6</month>
                <year>2021</year>
              </pub-date>
              <volume>10</volume>
              <issue seq="30">12</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v10.12</issue-id>
              <elocation-id>e020865</elocation-id>
              <history>
                <date date-type="received">
                  <day>15</day>
                  <month>1</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>14</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <!--Copyright &#x000a9; 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell-->
                <copyright-statement content-type="article-copyright">© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-10-e020865.pdf"/>
              <abstract id="jah36326-abs-0001">
                <sec id="jah36326-sec-0001">
                  <title>Background</title>
                  <p>Low‐level tragus stimulation (LLTS) has been shown to significantly reduce atrial fibrillation (AF) burden in patients with paroxysmal AF. P‐wave alternans (PWA) is believed to be generated by the same substrate responsible for AF. Hence, PWA may serve as a marker in guiding LLTS therapy. We investigated the utility of PWA in guiding LLTS therapy in patients with AF.</p>
                </sec>
                <sec id="jah36326-sec-0002">
                  <title>Methods and Results</title>
                  <p>Twenty‐eight patients with AF were randomized to either active LLTS or sham (earlobe stimulation). LLTS was delivered through a transcutaneous electrical nerve stimulation device (pulse width 200 μs, frequency 20 Hz, amplitude 10–50 mA), for 1 hour daily over a 6‐month period. AF burden over 2‐week periods was assessed by noninvasive continuous ECG monitoring at baseline, 3 months, and 6 months. A 5‐minute control ECG for PWA analysis was recorded during all 3 follow‐up visits. Following the control ECG, an additional 5‐minute ECG was recorded during active LLTS in all patients. At baseline, acute LLTS led to a significant rise in PWA burden. However, active patients receiving chronic LLTS demonstrated a significant reduction in both PWA and AF burden after 6 months (<italic toggle="yes">P</italic>&lt;0.05). Active patients who demonstrated an increase in PWA burden with acute LLTS showed a significant drop in AF burden after 6 months of chronic LLTS.</p>
                </sec>
                <sec id="jah36326-sec-0003">
                  <title>Conclusions</title>
                  <p>Chronic, intermittent LLTS resulted in lower PWA and AF burden than did sham control stimulation. Our results support the use of PWA as a potential marker for guiding LLTS treatment of paroxysmal AF.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd id="jah36326-kwd-0001">atrial fibrillation</kwd>
                <kwd id="jah36326-kwd-0002">P‐wave alternans</kwd>
                <kwd id="jah36326-kwd-0003">spectral method</kwd>
                <kwd id="jah36326-kwd-0004">vagal stimulation</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Atrial Fibrillation</kwd>
                <kwd>Electrophysiology</kwd>
                <kwd>Autonomic Nervous System</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>NIH
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000002</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>1 R01 HL135335‐01</award-id>
                  <award-id>1 R21 HL137870‐01</award-id>
                  <award-id>1 R21EB026164‐01</award-id>
                  <award-id>8UL1TR000170‐05</award-id>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>
                    <institution-wrap>
                      <institution>NIGMS
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000057</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>8P20GM103447</award-id>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>
                    <institution-wrap>
                      <institution>American Heart Association
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000968</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>15MCPRP2579000</award-id>
                  <award-id>15GRNT23070001</award-id>
                </award-group>
                <award-group id="funding-0004">
                  <funding-source>Institute of Precision Medicine</funding-source>
                  <award-id>17UNPG33840017</award-id>
                </award-group>
                <award-group id="funding-0005">
                  <funding-source>RICBAC Foundation</funding-source>
                </award-group>
                <award-group id="funding-0006">
                  <funding-source>
                    <institution-wrap>
                      <institution>Harvard Catalyst
</institution>
                      <institution-id institution-id-type="doi">10.13039/100007299</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0007">
                  <funding-source>
                    <institution-wrap>
                      <institution>Harvard Clinical and Translational Science Center
</institution>
                      <institution-id institution-id-type="doi">10.13039/100007299</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0008">
                  <funding-source>
                    <institution-wrap>
                      <institution>Harvard University
</institution>
                      <institution-id institution-id-type="doi">10.13039/100007229</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="6"/>
                <table-count count="2"/>
                <page-count count="31"/>
                <word-count count="13298"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>June 15, 2021</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.2 mode:remove_FC converted:15.06.2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jah36326-cit-1001">(<source>J Am Heart Assoc</source>. <year>2021</year>;<volume>10</volume>:<elocation-id>e020865</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/JAHA.120.020865</pub-id>.)<pub-id pub-id-type="pmid">34075778</pub-id></mixed-citation>
              </p>
              <fn-group id="jah36326-ntgp-0001">
                <fn id="jah36326-note-0001">
                  <p>Supplementary Material for this article is available at <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.120.020865" ext-link-type="uri">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.120.020865</ext-link>
</p>
                </fn>
                <fn id="jah36326-note-0002">
                  <p>For Sources of Funding and Disclosures, see page 8.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="jah36326-body-0001">
            <def-list list-content="abbreviations" id="jah36326-lp-0001">
              <title>Nonstandard Abbreviations and Acronyms</title>
              <def-item>
                <term>AA</term>
                <def>
                  <p>atrial alternans</p>
                </def>
              </def-item>
              <def-item>
                <term>HRV</term>
                <def>
                  <p>heart rate variability</p>
                </def>
              </def-item>
              <def-item>
                <term>LLTS</term>
                <def>
                  <p>low‐level transcutaneous VNS/low‐level tragus stimulation</p>
                </def>
              </def-item>
              <def-item>
                <term>PWA</term>
                <def>
                  <p>P‐wave alternans</p>
                </def>
              </def-item>
              <def-item>
                <term>VNS</term>
                <def>
                  <p>vagus nerve stimulation</p>
                </def>
              </def-item>
            </def-list>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah36326-blkfxd-0001">
                <sec id="jah36326-sec-0005">
                  <title>Clinical Perspective</title>
                  <sec id="jah36326-sec-0006">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah36326-list-0001">
                        <list-item>
                          <p>Chronic low‐level transcutaneous electrical stimulation of the tragus (LLTS) of the ear significantly lowers both P‐wave alternans (PWA) and atrial fibrillation (AF) burden in patients with paroxysmal AF.</p>
                        </list-item>
                        <list-item>
                          <p>While acute LLTS causes an increase in PWA, chronic LLTS leads to a decrease in PWA, and an acute increase in PWA at baseline predicts lower AF burden at follow‐up.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah36326-sec-0007">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah36326-list-0002">
                        <list-item>
                          <p>Chronic LLTS may be used as an alternative treatment option in selected patients with AF, and PWA may serve as a potential biomarker for identifying patients who are most likely to benefit from LLTS, guiding treatment of paroxysmal AF.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec sec-type="opening-section" id="jah36326-sec-0008">
              <p>Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, accounting for approximately one third of hospitalizations for cardiac rhythm disturbances.<xref rid="jah36326-bib-0001" ref-type="bibr"><sup>1</sup></xref> AF has been associated with significant morbidity and decline of quality of life.<xref rid="jah36326-bib-0002" ref-type="bibr"><sup>2</sup></xref>
</p>
              <p>Recent evidence suggests that the autonomic nervous system plays a central role in the pathogenesis of AF, especially in the early stages,<xref rid="jah36326-bib-0003" ref-type="bibr"><sup>3</sup></xref> and several studies<xref rid="jah36326-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="jah36326-bib-0005" ref-type="bibr"><sup>5</sup></xref> have shown that autonomic modulation with vagus nerve stimulation (VNS) can suppress AF in experimental models.<xref rid="jah36326-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="jah36326-bib-0005" ref-type="bibr"><sup>5</sup></xref> More recently, in a proof‐of‐concept study in humans, we showed that in patients with drug‐refractory AF undergoing AF ablation, noninvasive low‐level transcutaneous VNS (LLTS) for just 1 hour significantly shortened AF duration and decreased inflammatory cytokines.<xref rid="jah36326-bib-0006" ref-type="bibr"><sup>6</sup></xref> A recent clinical trial TREAT‐AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation) demonstrated that LLTS for 1 hour daily can significantly reduce AF burden in ambulatory patients with paroxysmal AF over a 6‐month period.<xref rid="jah36326-bib-0007" ref-type="bibr"><sup>7</sup></xref> Yet, the response to LLTS has been variable among individual patients, highlighting the need to optimize patient selection, in order to maximize the efficacy of this novel therapeutic strategy.</p>
              <p>Given the evidence supporting the role of atrial alternans (AA) promoting an arrhythmogenic atrial substrate<xref rid="jah36326-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="jah36326-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jah36326-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="jah36326-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="jah36326-bib-0012" ref-type="bibr"><sup>12</sup></xref> or being a precursor to AF,<xref rid="jah36326-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="jah36326-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="jah36326-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="jah36326-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="jah36326-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="jah36326-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="jah36326-bib-0017" ref-type="bibr"><sup>17</sup></xref> we hypothesized that P‐wave alternans (PWA), a subtle beat‐to‐beat variation in the morphology of the atrial electrocardiographic waveform, can be used as a biomarker to assess the effect of LLTS on AF burden and thus guide patient selection.</p>
            </sec>
            <sec sec-type="methods" id="jah36326-sec-0009">
              <title>Methods</title>
              <p>The data used in the analysis will be available to any investigator, upon request.</p>
              <sec id="jah36326-sec-0010">
                <title>Human Study</title>
                <p>This is an ancillary study of the recently published TREAT AF randomized clinical trial<xref rid="jah36326-bib-0007" ref-type="bibr"><sup>7</sup></xref>; the last 28 patients were included in this ancillary study, after modification of the original protocol. In brief, patients with paroxysmal AF, who had at least 2 documented episodes of AF within 3 months of randomization, were eligible for inclusion in the study. Exclusion criteria included left ventricular ejection fraction &lt;40%, significant valvular disease, recent (&lt;6 months) stroke or myocardial infarction, severe heart failure (New York Heart Association class III or IV), recurrent vasovagal syncopal episodes, unilateral or bilateral vagotomy, and pregnancy or nursing. In addition, we excluded patients with sick sinus syndrome, second‐ or third‐degree atrioventricular block, bifascicular block and prolonged first‐degree atrioventricular block (PR &gt;300 ms), in the absence of a pacemaker. The study was approved by the Institutional Review Board of the University of Oklahoma Health Sciences Center and patients provided informed consent before enrollment in the study. Enrollment in this study started after amendment of the original protocol. Thus, a total of 28 patients were enrolled in this study. A schematic of the study protocol is presented in Figure <xref rid="jah36326-fig-0001" ref-type="fig">1</xref>.</p>
                <fig position="float" fig-type="Figure" id="jah36326-fig-0001">
                  <label>Figure 1</label>
                  <caption>
                    <title>Schematic depicting the experimental protocol.</title>
                    <p>Patients with paroxysmal AF were randomized into sham (no chronic LLTS) and active (chronic LLTS) groups. Ten minutes of ECG was recorded at baseline, 3‐month, and 6‐month follow‐up visits, wherein 5 minutes were recorded during control (no acute LLTS), and 5 minutes during acute LLTS. Two weeks of noninvasive ECG monitoring both before and after the 6‐month study duration was performed to calculate AF burden before and after LLTS treatment. AF indicates atrial fibrillation; HRV, heart rate variability; and LLTS, low‐level tragus stimulation. * denotes sham or active group.</p>
                  </caption>
                  <graphic xlink:href="JAH3-10-e020865-g001" position="anchor" id="jats-graphic-1"/>
                </fig>
                <sec id="jah36326-sec-0011">
                  <title>Low‐Level Tragus Stimulation</title>
                  <p>Patients were randomized to either active or sham LLTS groups. LLTS was delivered by the patients themselves at home after individual training, through a transcutaneous electrical nerve stimulation device (Parasym device, Parasym Health, Inc, London, UK) for 1 hour daily over a 6‐month period. Active LLTS was accomplished by attaching an ear clip to the tragus, which is innervated by the auricular branch of the vagus nerve.<xref rid="jah36326-bib-0018" ref-type="bibr"><sup>18</sup></xref> Sham stimulation was delivered to the earlobe, which is devoid of vagal innervation.<xref rid="jah36326-bib-0018" ref-type="bibr"><sup>18</sup></xref> The device was set at a pulse width of 200 μs and a pulse frequency of 20 Hz. The stimulation strength was gradually increased until the patient experienced mild discomfort, then decreased by 1 mA below that threshold.</p>
                </sec>
                <sec id="jah36326-sec-0012">
                  <title>Patient Follow‐up</title>
                  <p>All patients were followed for 6 months. AF burden, defined as the percent of time spent in AF over a 2‐week period, was assessed by noninvasive continuous ECG monitoring (Ziopatch; iRythm Technologies, Inc, San Francisco, CA) at baseline, at 3 months, and at 6 months. A 5‐minute ECG was recorded as control for heart rate variability (HRV) and PWA analysis at each visit (baseline, 3 months and 6 months), using a PC‐based ECG machine (SE 1515; Edan USA, Inc) with a sampling rate of 1000 Hz. Immediately after the control ECG, an additional 5‐minute ECG was performed during active LLTS in all patients (active and sham), irrespective of randomization group (Figure <xref rid="jah36326-fig-0001" ref-type="fig">1</xref>), to gauge the acute effects of LLTS at each time point. Hence, while active patients effectively received both chronic and acute LLTS, sham patients received only acute LLTS.</p>
                </sec>
              </sec>
              <sec id="jah36326-sec-0013">
                <title>AA Estimation</title>
                <p>Extensive prior work by our laboratory has established the ability of microvolt T‐wave alternans to predict short‐<xref rid="jah36326-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="jah36326-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="jah36326-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="jah36326-bib-0022" ref-type="bibr"><sup>22</sup></xref> and long‐term<xref rid="jah36326-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="jah36326-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="jah36326-bib-0025" ref-type="bibr"><sup>25</sup></xref> susceptibility to ventricular tachyarrhythmias and sudden cardiac death. We have customized an algorithm currently used for estimating ventricular T‐wave alternans so that it can be applied to estimating AA. Further details of the algorithm are presented in Data <xref rid="jah36326-sup-0001" ref-type="supplementary-material">S1</xref>.</p>
                <p>We estimated the level of PWA reflecting atrial depolarization (details presented in Data <xref rid="jah36326-sup-0001" ref-type="supplementary-material">S1</xref>), during control (no stimulation) and LLTS (acute tragus stimulation), for sham and active groups at baseline, 3 months, and 6 months.</p>
              </sec>
              <sec id="jah36326-sec-0014">
                <title>AA Burden</title>
                <p>Estimates of alternans voltage and K<sub>score</sub> were generated based on the spectral method as previously described.<xref rid="jah36326-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="jah36326-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="jah36326-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="jah36326-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="jah36326-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="jah36326-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="jah36326-bib-0026" ref-type="bibr"><sup>26</sup></xref>, <xref rid="jah36326-bib-0027" ref-type="bibr"><sup>27</sup></xref> Briefly, for each estimate, a matrix of 128 beats was used in which a window that reflected the atrial depolarization for each beat was created. Then, the power spectrum was estimated for each time‐aligned sequence of sample points (Figure <xref rid="jah36326-fig-0002" ref-type="fig">2</xref>), within the selected atrial waveform (ie, P‐wave reflecting atrial depolarization).<xref rid="jah36326-bib-0026" ref-type="bibr"><sup>26</sup></xref> Subsequently, the power spectra for all sample points within the waveform were averaged and the statistical estimates of alternans (ie, alternans voltage, noise, and K<sub>score</sub>), were obtained.<xref rid="jah36326-bib-0026" ref-type="bibr"><sup>26</sup></xref> The alternans voltage is a direct measure of the presence of alternans, while the K<sub>score</sub> is a measure of the statistical significance of the alternans voltage (Figure <xref rid="jah36326-fig-0002" ref-type="fig">2</xref>). Once estimates of alternans voltage and K<sub>score</sub> were generated (for more details, please see Data <xref rid="jah36326-sup-0001" ref-type="supplementary-material">S1</xref>), we calculated PWA burden for each patient as follows:<disp-formula id="jah36326-disp-0001"><mml:math id="jats-math-1" display="block"><mml:mrow><mml:mtext>PWA burden</mml:mtext><mml:mo>=</mml:mo><mml:mtext>positive PWA sequences/total sequences</mml:mtext><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where a positive PWA sequence was defined as any 128‐beat sequence with K<sub>score</sub> &gt;3, alternans voltage &gt;0.5 μV, and goodbeat % &gt;80. In addition, ECG recordings with at least 50 good sequences across all leads were used for analysis.</p>
                <fig position="float" fig-type="Figure" id="jah36326-fig-0002">
                  <label>Figure 2</label>
                  <caption>
                    <title>Spectral method for estimation of P‐wave alternans.</title>
                    <p><bold>A</bold>, One hundred twenty‐eight time‐aligned (with respect to the R‐wave peak) P‐wave points that are used in the power spectrum estimation. <bold>B</bold>, Representative example of power spectrum of beat‐to‐beat fluctuations in P‐wave morphology. The alternans voltage is the square root of the amplitude of the power spectrum at the alternans frequency (alternans peak) minus the mean background noise level (μ<sub>noise</sub>). The alternans ratio, K<sub>score</sub>, is the amplitude of the spectrum at the alternans frequency (alternans peak) minus the mean background noise level (μ<sub>noise</sub>), divided by the SD of the noise (σ<sub>noise</sub>) in the reference noise band.</p>
                  </caption>
                  <graphic xlink:href="JAH3-10-e020865-g002" position="anchor" id="jats-graphic-3"/>
                </fig>
              </sec>
              <sec id="jah36326-sec-0015">
                <title>Effect of Vagal Stimulation on HRV</title>
                <p>We further sought to evaluate the effect of VNS on HRV. Clinically, high HRV has been associated with healthy cardiac tissue<xref rid="jah36326-bib-0028" ref-type="bibr"><sup>28</sup></xref> while low HRV has been correlated with increased risk of lethal ventricular arrhythmias and sudden death.<xref rid="jah36326-bib-0029" ref-type="bibr"><sup>29</sup></xref> Hence, evaluation of HRV has become an important method for assessing cardiac autonomic regulation. Here we calculated both linear time domain and nonlinear measures of HRV to gauge the effect of LLTS on autonomic regulation. Detailed methods documenting the calculation of individual HRV parameters are presented in Data <xref rid="jah36326-sup-0001" ref-type="supplementary-material">S1</xref>.</p>
              </sec>
              <sec id="jah36326-sec-0016">
                <title>Statistical Analysis</title>
                <p>For each subject, sequences across all 12 leads with the number of good beats exceeding 80% and no respiration interference were combined to calculate the mean value, presented here. ECG recordings that did not meet the good beat threshold and did not have at least 50 good sequences were excluded from​ the analysis.</p>
                <p>Continuous data are presented as mean±SD or median and interquartile range, as applicable. Categorical data are presented as percentages. Comparisons of continuous data were performed using a mixed linear model, with adjustment for the respective baseline values. Significant group‐by‐time interactions were followed by time‐stratified analyses. For all pairwise testing, we adjusted for multiple comparisons using Tukey's method. The association of PWA burden with AF burden was examined using a polynomial, as well as logistic regression model, after adjustment for baseline values. Logarithmic transformation was performed as appropriate, to satisfy the model assumptions of normality and homoscedasticity. Categorical data were compared using Fisher's exact test. Values of <italic toggle="yes">P</italic>&lt;0.05 were considered statistically significant. Statistical analysis was performed using SAS software version 9.4 (SAS Institute, Cary, NC) and MATLAB (MathWorks Inc, Natick, MA).</p>
                <p>In figures, data are presented as median (horizontal solid line), 75% to 25% percentiles (box), and 90% to 10% percentiles (error bars).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jah36326-sec-0017">
              <title>Results</title>
              <sec id="jah36326-sec-0018">
                <title>Patient Population</title>
                <p>The baseline clinical characteristics of the patients enrolled in this study are summarized in Table <xref rid="jah36326-tbl-0001" ref-type="table">1</xref>. Of the 28 patients enrolled at baseline, n=12 were randomized to sham and n=16 were randomized to the active LLTS group. There were no differences in clinical characteristics between the sham and active LLTS groups. Four patients (2 in each group) withdrew consent after 3 months of being in the study, while 1 patient in the sham group died of myocardial infarction. The rest of the patients completed the entire study. The stimulation intensity was similar in the 2 groups (sham 18.9±9.3 mA versus LLTS: 16.2±8.5 mA; <italic toggle="yes">P</italic>=0.42). No device‐related adverse events were reported.</p>
                <table-wrap position="float" id="jah36326-tbl-0001" content-type="Table">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline Characteristics of the Patient Population</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="center" valign="top" rowspan="1" colspan="1">Sham (n=12)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Active (n=16)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age, y</td>
                        <td align="left" rowspan="1" colspan="1">60.3±12.5</td>
                        <td align="left" rowspan="1" colspan="1">66.3±7.6</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.17</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Female sex, %</td>
                        <td align="left" rowspan="1" colspan="1">6 (50)</td>
                        <td align="left" rowspan="1" colspan="1">8 (50)</td>
                        <td align="char" char="." rowspan="1" colspan="1">1.0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">31.7±5.4</td>
                        <td align="left" rowspan="1" colspan="1">30.6±8.2</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.71</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diabetes mellitus, %</td>
                        <td align="left" rowspan="1" colspan="1">3 (25)</td>
                        <td align="left" rowspan="1" colspan="1">3 (19)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.28</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hypertension, %</td>
                        <td align="left" rowspan="1" colspan="1">9 (75)</td>
                        <td align="left" rowspan="1" colspan="1">12 (75)</td>
                        <td align="char" char="." rowspan="1" colspan="1">1.0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Coronary artery disease, %</td>
                        <td align="left" rowspan="1" colspan="1">4 (33)</td>
                        <td align="left" rowspan="1" colspan="1">5 (31)</td>
                        <td align="char" char="." rowspan="1" colspan="1">1.0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Heart failure, %</td>
                        <td align="left" rowspan="1" colspan="1">3 (25)</td>
                        <td align="left" rowspan="1" colspan="1">3 (19)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.59</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Obstructive sleep apnea, %</td>
                        <td align="left" rowspan="1" colspan="1">5 (42)</td>
                        <td align="left" rowspan="1" colspan="1">5 (31)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.58</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Antiarrhythmic drugs, %</td>
                        <td align="left" rowspan="1" colspan="1">7 (58)</td>
                        <td align="left" rowspan="1" colspan="1">5 (31)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.14</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Years in atrial fibrillation</td>
                        <td align="left" rowspan="1" colspan="1">6.0±5.3</td>
                        <td align="left" rowspan="1" colspan="1">4.1±3.3</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.37</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">CHADS<sub>2</sub>‐VA<sub>2</sub>Sc score</td>
                        <td align="left" rowspan="1" colspan="1">2.6±1.7</td>
                        <td align="left" rowspan="1" colspan="1">3.0±1.7</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.61</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Left ventricular ejection fraction, %</td>
                        <td align="left" rowspan="1" colspan="1">57.7±7.7</td>
                        <td align="left" rowspan="1" colspan="1">62.4±6.8</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.18</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Left atrial diameter, cm</td>
                        <td align="left" rowspan="1" colspan="1">4.8±1.0</td>
                        <td align="left" rowspan="1" colspan="1">4.6±0.6</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.68</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Medical therapy</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Beta blockers</td>
                        <td align="left" rowspan="1" colspan="1">11 (92)</td>
                        <td align="left" rowspan="1" colspan="1">14 (88)</td>
                        <td align="char" char="." rowspan="1" colspan="1">1.0</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Calcium channel blockers</td>
                        <td align="left" rowspan="1" colspan="1">5 (42)</td>
                        <td align="left" rowspan="1" colspan="1">4 (25)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.43</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Class I antiarrhythmics</td>
                        <td align="left" rowspan="1" colspan="1">4 (33)</td>
                        <td align="left" rowspan="1" colspan="1">4 (25)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.69</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Class III antiarrhythmics</td>
                        <td align="left" rowspan="1" colspan="1">2 (17)</td>
                        <td align="left" rowspan="1" colspan="1">1 (6)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.56</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah36326-ntgp-0002">
                    <fn id="jah36326-note-0003">
                      <p>Numbers in parentheses reflect percentages.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="jah36326-sec-0019">
                <title>Effect of Chronic LLTS on Heart Rate, HRV, P‐Wave Duration, QT, QTc, PR, and Tpeak‐Tend</title>
                <p>We first evaluated the effect of LLTS on heart rate for both sham and active patients. No significant changes were observed with chronic LLTS on either group, indicating that the selected stimulation parameters did not cause a change in resting heart rate (Figures <xref rid="jah36326-sup-0001" ref-type="supplementary-material">S1 and S2</xref>). Chronic LLTS did not significantly alter any ECG parameter, including P‐wave duration, QT‐interval, QTc (QT interval corrected for heart rate), PR‐interval, and Tpeak‐Tend interval (Figures <xref rid="jah36326-sup-0001" ref-type="supplementary-material">S3 through S7</xref>). Summary results of chronic LLTS on different HRV measures, namely, SD of RR interval, root mean square of the successive differences of RR intervals, NN<sub>50</sub> count, pNN<sub>50</sub>, and SD2/SD1 ratio presented in Data <xref rid="jah36326-sup-0001" ref-type="supplementary-material">S1</xref> have shown mostly no differences between groups (Figures <xref rid="jah36326-sup-0001" ref-type="supplementary-material">S8 through S12</xref>).</p>
              </sec>
              <sec id="jah36326-sec-0020">
                <title>Effect of Chronic LLTS on PWA and AF Burden</title>
                <p>Figure <xref rid="jah36326-fig-0003" ref-type="fig">3</xref> demonstrates summary results of chronic LLTS on AF burden across all active and sham patients. AF burden was significantly lower in the active group compared with sham, after 6 months of chronic LLTS. Figure <xref rid="jah36326-fig-0004" ref-type="fig">4</xref> demonstrates summary results of chronic LLTS on PWA burden during control conditions (no acute LLTS), across all active and sham patients. Similar to AF burden, PWA burden was significantly lower in the active group compared with sham, after 6 months of chronic LLTS. A summary of AF burden and PWA burden at the respective time points is shown in Table <xref rid="jah36326-tbl-0002" ref-type="table">2</xref>. Summary results of chronic LLTS on PWA voltage and K<sub>score</sub> are presented in Figures <xref rid="jah36326-sup-0001" ref-type="supplementary-material">S13 through S16</xref>.</p>
                <fig position="float" fig-type="Figure" id="jah36326-fig-0003">
                  <label>Figure 3</label>
                  <caption>
                    <title>Chronic effects of LLTS on AF burden in active and sham patients.</title>
                    <p>There has been a statistically significant decrease of AF burden at 6 months in the active group compared with sham. The <italic toggle="yes">P</italic> value is based on a comparison of median AF burden levels at the 6‐month time point after adjusting for baseline measures. “*” denotes statistical significance of <italic toggle="yes">P</italic>&lt;0.05. AF indicates atrial fibrillation; and LLTS, low‐level tragus stimulation.</p>
                  </caption>
                  <graphic xlink:href="JAH3-10-e020865-g006" position="anchor" id="jats-graphic-5"/>
                </fig>
                <fig position="float" fig-type="Figure" id="jah36326-fig-0004">
                  <label>Figure 4</label>
                  <caption>
                    <title>Chronic effects of LLTS on PWA burden in active and sham patients.</title>
                    <p>There has been a statistically significant decrease of PWA burden at 6 months in the active group compared with sham. The <italic toggle="yes">P</italic> value is based on a comparison of median PWA burden levels at the 6‐month time point after adjusting for baseline measures. “*” denotes statistical significance of <italic toggle="yes">P</italic>&lt;0.05. LLTS indicates low‐level tragus stimulation; and PWA, P‐wave alternans.</p>
                  </caption>
                  <graphic xlink:href="JAH3-10-e020865-g004" position="anchor" id="jats-graphic-7"/>
                </fig>
                <table-wrap position="float" id="jah36326-tbl-0002" content-type="Table">
                  <label>Table 2</label>
                  <caption>
                    <p>Summary of AF Burden and PWA Burden at Baseline and Follow‐up</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" valign="top" colspan="1"/>
                        <th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">AF Burden (%)</th>
                        <th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">PWA Burden (%)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="center" valign="top" rowspan="1" colspan="1">Sham</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Active</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Sham</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Active</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline</td>
                        <td align="char" char="." rowspan="1" colspan="1">13.0±13.1</td>
                        <td align="char" char="." rowspan="1" colspan="1">14.3±12.2</td>
                        <td align="char" char="." rowspan="1" colspan="1">9.6±8.1</td>
                        <td align="char" char="." rowspan="1" colspan="1">8.2±7.7</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">3 mo</td>
                        <td align="char" char="." rowspan="1" colspan="1">15.2±13.9</td>
                        <td align="char" char="." rowspan="1" colspan="1">12.7±9.2</td>
                        <td align="char" char="." rowspan="1" colspan="1">11.2±8.9</td>
                        <td align="char" char="." rowspan="1" colspan="1">8.1±6.0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">6 mo</td>
                        <td align="char" char="." rowspan="1" colspan="1">25.7±16.6</td>
                        <td align="char" char="." rowspan="1" colspan="1">10.3±8.7<xref rid="jah36326-note-0005" ref-type="table-fn">*</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">13.9±9.7</td>
                        <td align="char" char="." rowspan="1" colspan="1">7.7±3.5<xref rid="jah36326-note-0005" ref-type="table-fn">*</xref>
</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah36326-ntgp-0003">
                    <fn id="jah36326-note-0004">
                      <p>AF indicates atrial fibrillation; and PWA, P‐wave alternans.</p>
                    </fn>
                    <fn id="jah36326-note-0005">
                      <label>*</label>
                      <p><italic toggle="yes">P</italic>&lt;0.05 vs sham.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="jah36326-sec-0021">
                <title>Effect of Acute LLTS on PWA</title>
                <p>Figures <xref rid="jah36326-fig-0005" ref-type="fig">5A and 5B</xref> demonstrate summary results of acute LLTS on PWA burden during control conditions (no stimulation) and LLTS at baseline, before commencement of chronic active LLTS. Acute LLTS led to a significant increase in PWA burden. Figure <xref rid="jah36326-fig-0005" ref-type="fig">5B</xref> demonstrates summary results of the effect of acute LLTS on ΔPWA burden at 3 and 6 months. Change in PWA burden because of acute LLTS compared with control conditions (no stimulation) was evaluated at each time point. ΔPWA burden was significantly lower in the active group compared with sham with acute stimulation at 6 months, suggesting that chronic LLTS modified the effect of acute LLTS over time.</p>
                <fig position="float" fig-type="Figure" id="jah36326-fig-0005">
                  <label>Figure 5</label>
                  <caption>
                    <title>Effect of LLTS on PWA at baseline and follow‐up.</title>
                    <p>Summary results of acute LLTS on PWA burden at baseline, for all patients (<bold>A</bold>). In (<bold>B</bold>), the change in PWA burden before and after acute LLTS was compared between the 2 groups at 3 and 6 months of follow‐up. At 6 months, acute LLTS in the LLTS group resulted in a favorable decrease in PWA burden, which was significantly different than the respective change in the sham group. “*” denotes statistical significance of <italic toggle="yes">P</italic>&lt;0.05. CRTL indicates control; LLTS, low‐level tragus stimulation; and PWA, P‐wave alternans.</p>
                  </caption>
                  <graphic xlink:href="JAH3-10-e020865-g005" position="anchor" id="jats-graphic-9"/>
                </fig>
              </sec>
              <sec id="jah36326-sec-0022">
                <title>Identifying Early Markers of Effective LLTS Treatment</title>
                <p>Given that not all active patients had a similar response to chronic LLTS, we sought to identify whether patients who produced an early indicative response to acute LLTS also demonstrated a response to chronic therapy, hence aiding us in identifying potential biomarkers for effective LLTS treatment. Patients in the active group were categorized into 2 subgroups based on their initial response to LLTS: A1, patients with an initial increase in PWA burden during acute LLTS at baseline (n=8) and A2, patients with no increase in PWA burden during acute LLTS at baseline (n=8). Patients in group A1 had significantly lower AF burden at 6 months compared with group A2 (Figure <xref rid="jah36326-fig-0006" ref-type="fig">6A</xref>). Using logistic regression analysis, an acute increase of PWA at baseline predicted a significant decrease in AF burden at 6 months (odds ratio, 0.4; 95% CI, 0.17–0.94, <italic toggle="yes">P</italic>=0.03). In addition, at the individual patient level, there was a significant negative linear association between the change in AF burden and PWA burden from baseline to 6 months with acute stimulation, suggesting that an acute increase in PWA at baseline predicts lower AF burden at follow‐up and may be used as a biomarker of response to chronic LLTS (Figure <xref rid="jah36326-fig-0006" ref-type="fig">6B</xref>).</p>
                <fig position="float" fig-type="Figure" id="jah36326-fig-0006">
                  <label>Figure 6</label>
                  <caption>
                    <title>Response to chronic LLTS, according to the baseline acute response to LLTS.</title>
                    <p><bold>A</bold>, Patients in the active group were categorized into 2 subgroups based on their initial response to LLTS. A1, patients with an initial increase in PWA burden during acute LLTS at baseline and A2, patients with no increase in PWA burden during acute LLTS at baseline. Patients in group A1 had a significant decrease in AF burden at 6 months, whereas AF burden did not improve with chronic LLTS in group A2. <bold>B</bold>, Scatter plot of change in AF burden with respect to change in PWA burden for each patient (blue dot). At the individual patient level, there was a significant negative linear association between the change in AF burden and the change in PWA burden, from baseline to 6 months, with acute stimulation. Collectively, these data suggest that acute change in PWA at baseline may be used as a biomarker of response to chronic LLTS. N=14, because 2 active patients did not complete the 6‐month follow‐up. “*” denotes statistical significance of <italic toggle="yes">P</italic>&lt;0.05. AF indicates atrial fibrillation; LLTS, low‐level tragus stimulation; and PWA, P‐wave alternans.</p>
                  </caption>
                  <graphic xlink:href="JAH3-10-e020865-g003" position="anchor" id="jats-graphic-11"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion" id="jah36326-sec-0023">
              <title>Discussion</title>
              <p>With increasing life expectancy and greater burden of chronic medical conditions, AF has become increasingly prevalent in the population and remains a major source of morbidity and mortality because of limited, and often ineffective treatment options.<xref rid="jah36326-bib-0001" ref-type="bibr"><sup>1</sup></xref> Although LLTS has emerged as a promising new treatment modality, it remains hampered by the lack of a biomarker to guide patient selection and stimulation parameters. The major findings of this study are as follows: (1) chronic LLTS significantly lowers both PWA and AF burden in patients with paroxysmal AF; (2) LLTS modulates the level of PWA; acute LLTS causes an increase in PWA, while chronic LLTS leads to a decrease in PWA; and (3) PWA can serve as a marker of LLTS efficacy and guide its use in patients with AF; patients who show an early indicative increase in PWA burden because of acute LLTS demonstrate favorable effects of chronic LLTS treatment, highlighting the utility of PWA in identifying patients most likely to benefit from LLTS treatment.</p>
              <p>The first trial that evaluated the effect of VNS in patients with heart failure, an open label, nonrandomized pilot trial, demonstrated that VNS resulted in significant improvement in functional class, quality of life, 6‐minute walk test, and left‐ventricular end‐systolic volume, in the absence of any major side effects.<xref rid="jah36326-bib-0030" ref-type="bibr"><sup>30</sup></xref> Despite these early promising results, 3 subsequent randomized trials of VNS in heart failure showed either neutral effects,<xref rid="jah36326-bib-0031" ref-type="bibr"><sup>31</sup></xref>, <xref rid="jah36326-bib-0032" ref-type="bibr"><sup>32</sup></xref> or only mild benefit.<xref rid="jah36326-bib-0033" ref-type="bibr"><sup>33</sup></xref> The rather disappointing results of these trials, despite the clear rationale for decreasing sympathovagal imbalance in heart failure, highlight the notion that optimizing patient selection and stimulation parameters are crucial to elucidate the possible patient‐specific favorable effects of VNS.<xref rid="jah36326-bib-0034" ref-type="bibr"><sup>34</sup></xref>
</p>
              <p>In the current study, we observed that individual patient response to LLTS can vary greatly. While some active patients showed no observable response to chronic LLTS, in some patients a significant drop in PWA burden was observed. Additionally, response to acute and chronic LLTS was contradictory. Acute LLTS at baseline tended to increase the level of PWA in patients, yet, after 3 or 6 months of chronic LLTS, active patients showed a drop in alternans level with acute LLTS compared with control conditions (no stimulation). This is possibly indicative of chronic LLTS inducing positive changes in the atrial electrical substrate over time, making it more conducive to vagal stimulation and leading to a decrease in the overall level of alternans. Moreover, based on recent evidence that LLTS activates central vagal projections,<xref rid="jah36326-bib-0035" ref-type="bibr"><sup>35</sup></xref> we speculate that the effect of LLTS is because of, at least in part, favorable changes in the central nervous system.</p>
              <p>In light of the limitations associated with currently available end points pertinent to the effectiveness of VNS in patients with AF, a major advancement in this field will be achieved by determining the impact of VNS on the underlying atrial substrate and autonomic tone, and defining better metrics of immediate and long‐term response.<xref rid="jah36326-bib-0036" ref-type="bibr"><sup>36</sup></xref> In this study, we hypothesized that AA is associated with the same myocardial substrate that gives rise to AF and that modification of the AA level could serve as a marker of successful LLTS. Development of tools that can be applied in real‐time to determine optimal LLTS parameters to sufficiently modify the atrial substrate is critical to improving the efficacy of this novel therapeutic modality. If validated, in future prospective studies a process to optimally select candidate patients for LLTS, based on a novel physiological biomarker, PWA, which reflects the arrhythmogenic potential of the underlying atrial substrate and its modulation by LLTS resulting in a reduction in AF burden,<xref rid="jah36326-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jah36326-bib-0037" ref-type="bibr"><sup>37</sup></xref> could be a major improvement in the management of AF.</p>
              <p>The effect of VNS is critically dependent on stimulation parameters.<xref rid="jah36326-bib-0034" ref-type="bibr"><sup>34</sup></xref>, <xref rid="jah36326-bib-0036" ref-type="bibr"><sup>36</sup></xref>, <xref rid="jah36326-bib-0038" ref-type="bibr"><sup>38</sup></xref> Since autonomic tone differs among individual patients, it is possible that there is no single, “optimal” set of stimulation parameters for all patients. In the present study, low‐level intermittent VNS was performed with stimulation strength restricted to 1 mA below an individual patient's discomfort threshold. This prevented any sudden adverse effects on heart rate in both active and sham patients because of parasympathetic overdrive, as was evident from the lack of any significant changes in both heart rate and RR interval in all patients (Figures <xref rid="jah36326-sup-0001" ref-type="supplementary-material">S1 and S2</xref>). The absence of significant effects on heart rate variability measures with chronic parasympathetic stimulation can also be possibly attributed to the selection of low‐level intermittent VNS. However, since PWA is a substrate‐dependent phenomenon, its physiological mechanism differs from simple HR measures and hence, in the present study, both acute and chronic LLTS significantly modulated PWA. Therefore, upon further validation, PWA may serve as a biomarker to determine customized, optimal VNS parameters for each patient and thus optimally guide the management of AF.<xref rid="jah36326-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jah36326-bib-0037" ref-type="bibr"><sup>37</sup></xref> Furthermore, the present study could also serve as evidence for selection criteria for a broader longitudinal study of VNS in patients with AF so as to improve study outcomes in appropriately selected participants. Selecting patients who are likely to benefit from LLTS based on an acute biomarker of response will improve the overall response to LLTS and will thus increase the cost‐effectiveness of this novel therapy for AF. This notion warrants further investigation in future randomized clinical trials.</p>
              <sec id="jah36326-sec-0024">
                <title>Limitations</title>
                <p>This study has several limitations. First, this was a proof‐of‐concept study with a limited number of patients. Therefore, further validation is required in larger studies. Second, future studies should include continuous monitoring of AF to allow a more accurate assessment of AF burden. Third, stimulation of the earlobe in the sham group may have resulted in some effect, which in turn would minimize the effect of active LLTS. However, previous studies have shown that stimulation of the earlobe, in contrast to stimulation of the tragus, does not result in activation of central vagal projections,<xref rid="jah36326-bib-0035" ref-type="bibr"><sup>35</sup></xref> and therefore is a reasonable sham control. Finally, although other methods of AA calculation are available, the method used in this study has been previously validated by our group.<xref rid="jah36326-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jah36326-bib-0037" ref-type="bibr"><sup>37</sup></xref>
</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="jah36326-sec-0025">
              <title>Conclusions</title>
              <p>Chronic, intermittent LLTS resulted in lower PWA and AF burden than did sham control stimulation. Our results support the notion that PWA can be used as a potential biomarker for guiding LLTS treatment of paroxysmal AF.</p>
            </sec>
            <sec id="jah36326-sec-0026">
              <title>Sources of Funding</title>
              <p>The work was supported by a NIH/NIGMS grant #8P20GM103447, American Heart Association (#15MCPRP2579000), Grand‐in‐Aid (#15GRNT23070001) from the American Heart Association (AHA), the Institute of Precision Medicine (17UNPG33840017) from the AHA, the RICBAC Foundation, NIH grant 1 R01 HL135335‐01, 1 R21 HL137870‐01 and 1 R21EB026164‐01. This work was conducted with support from Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award 8UL1TR000170‐05 and financial contributions from Harvard University and its affiliated academic healthcare centers). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health.</p>
            </sec>
            <sec sec-type="COI-statement" id="jah36326-sec-0027">
              <title>Disclosures</title>
              <p>None.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="jah36326-sup-0001" position="float" content-type="local-data">
                <caption>
                  <p>Data S1</p>
                  <p>Figures S1–S16</p>
                </caption>
                <media xlink:href="JAH3-10-e020865-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ref-list content-type="cited-references" id="jah36326-bibl-0001">
              <title>References</title>
              <ref id="jah36326-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0001"><string-name><surname>Le Heuzey</surname><given-names>JY</given-names></string-name>, <string-name><surname>Paziaud</surname><given-names>O</given-names></string-name>, <string-name><surname>Piot</surname><given-names>O</given-names></string-name>, <string-name><surname>Said</surname><given-names>MA</given-names></string-name>, <string-name><surname>Copie</surname><given-names>X</given-names></string-name>, <string-name><surname>Lavergne</surname><given-names>T</given-names></string-name>, <string-name><surname>Guize</surname><given-names>L</given-names></string-name>. <article-title>Cost of care distribution in atrial fibrillation patients: the COCAF study</article-title>. <source>Am Heart J</source>. <year>2004</year>;<volume>147</volume>:<fpage>121</fpage>–<lpage>126</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/S0002-8703(03)00524-6</pub-id>.<pub-id pub-id-type="pmid">14691429</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0002"><string-name><surname>Miyasaka</surname><given-names>YBM</given-names></string-name>, <string-name><surname>Bailey</surname><given-names>KR</given-names></string-name>, <string-name><surname>Cha</surname><given-names>SS</given-names></string-name>, <string-name><surname>Gersh</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Seward</surname><given-names>JB</given-names></string-name>, <string-name><surname>Tsang</surname><given-names>TS</given-names></string-name>. <article-title>Mortality trends in patients diagnosed with first atrial fibrillation: a 21‐year community‐based study</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>49</volume>:<fpage>986</fpage>–<lpage>992</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jacc.2006.10.062</pub-id>
<pub-id pub-id-type="pmid">17336723</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0003"><string-name><surname>Stavrakis</surname><given-names>S</given-names></string-name>, <string-name><surname>Nakagawa</surname><given-names>H</given-names></string-name>, <string-name><surname>Po</surname><given-names>SS</given-names></string-name>, <string-name><surname>Scherlag</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Lazzara</surname><given-names>R</given-names></string-name>, <string-name><surname>Jackman</surname><given-names>WM</given-names></string-name>. <article-title>The role of the autonomic ganglia in atrial fibrillation</article-title>. <source>JACC Clin Electrophysiol</source>. <year>2015</year>;<volume>1</volume>:<fpage>1</fpage>–<lpage>13</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jacep.2015.01.005</pub-id>.<pub-id pub-id-type="pmid">26301262</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0004"><string-name><surname>Sheng</surname><given-names>X</given-names></string-name>, <string-name><surname>Scherlag</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name><surname>Li</surname><given-names>S</given-names></string-name>, <string-name><surname>Ali</surname><given-names>R</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Fu</surname><given-names>G</given-names></string-name>, <string-name><surname>Nakagawa</surname><given-names>H</given-names></string-name>, <string-name><surname>Jackman</surname><given-names>WM</given-names></string-name>, <string-name><surname>Lazzara</surname><given-names>R</given-names></string-name>, et al. <article-title>Prevention and reversal of atrial fibrillation inducibility and autonomic remodeling by low‐level vagosympathetic nerve stimulation</article-title>. <source>J Am Coll Cardiol</source>. <year>2011</year>;<volume>57</volume>:<fpage>563</fpage>–<lpage>571</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jacc.2010.09.034</pub-id>.<pub-id pub-id-type="pmid">21272747</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0005"><string-name><surname>Shen</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Shinohara</surname><given-names>T</given-names></string-name>, <string-name><surname>Park</surname><given-names>H‐W</given-names></string-name>, <string-name><surname>Frick</surname><given-names>K</given-names></string-name>, <string-name><surname>Ice</surname><given-names>DS</given-names></string-name>, <string-name><surname>Choi</surname><given-names>E‐K</given-names></string-name>, <string-name><surname>Han</surname><given-names>S</given-names></string-name>, <string-name><surname>Maruyama</surname><given-names>M</given-names></string-name>, <string-name><surname>Sharma</surname><given-names>R</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, et al. <article-title>Continuous low‐level vagus nerve stimulation reduces stellate ganglion nerve activity and paroxysmal atrial tachyarrhythmias in ambulatory canines</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>123</volume>:<fpage>2204</fpage>–<lpage>2212</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.018028</pub-id>.<pub-id pub-id-type="pmid">21555706</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0006"><string-name><surname>Stavrakis</surname><given-names>S</given-names></string-name>, <string-name><surname>Humphrey</surname><given-names>MB</given-names></string-name>, <string-name><surname>Scherlag</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Jackman</surname><given-names>WM</given-names></string-name>, <string-name><surname>Nakagawa</surname><given-names>H</given-names></string-name>, <string-name><surname>Lockwood</surname><given-names>D</given-names></string-name>, <string-name><surname>Lazzara</surname><given-names>R</given-names></string-name>, <string-name><surname>Po</surname><given-names>SS</given-names></string-name>. <article-title>Low‐level transcutaneous electrical vagus nerve stimulation suppresses atrial fibrillation</article-title>. <source>J Am Coll Cardiol</source>. <year>2015</year>;<volume>65</volume>:<fpage>867</fpage>–<lpage>875</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jacc.2014.12.026</pub-id>
<pub-id pub-id-type="pmid">25744003</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0007"><string-name><surname>Stavrakis</surname><given-names>S</given-names></string-name>, <string-name><surname>Stoner</surname><given-names>JA</given-names></string-name>, <string-name><surname>Humphrey</surname><given-names>MB</given-names></string-name>, <string-name><surname>Morris</surname><given-names>L</given-names></string-name>, <string-name><surname>Filiberti</surname><given-names>A</given-names></string-name>, <string-name><surname>Reynolds</surname><given-names>JC</given-names></string-name>, <string-name><surname>Elkholey</surname><given-names>K</given-names></string-name>, <string-name><surname>Javed</surname><given-names>I</given-names></string-name>, <string-name><surname>Twidale</surname><given-names>N</given-names></string-name>, <string-name><surname>Riha</surname><given-names>P</given-names></string-name>, et al. <article-title>TREAT AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation): a randomized clinical trial</article-title>. <source>JACC Clin Electrophysiol</source>. <year>2020</year>;<volume>6</volume>:<fpage>282</fpage>–<lpage>291</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jacep.2019.11.008</pub-id>.<pub-id pub-id-type="pmid">32192678</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0008"><string-name><surname>Chang</surname><given-names>KC</given-names></string-name>, <string-name><surname>Bayer</surname><given-names>JD</given-names></string-name>, <string-name><surname>Trayanova</surname><given-names>NA</given-names></string-name>. <article-title>Disrupted calcium release as a mechanism for atrial alternans associated with human atrial fibrillation</article-title>. <source>PLoS Comput Biol</source>. <year>2014</year>;<volume>10</volume>:<elocation-id>e1004011</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1371/journal.pcbi.1004011</pub-id>.<pub-id pub-id-type="pmid">25501557</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0009"><string-name><surname>Kanaporis</surname><given-names>G</given-names></string-name>, <string-name><surname>Blatter</surname><given-names>LA</given-names></string-name>. <article-title>Alternans in atria: mechanisms and clinical relevance</article-title>. <source>Medicina</source>. <year>2017</year>;<volume>53</volume>:<fpage>139</fpage>–<lpage>149</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.medici.2017.04.004</pub-id>.<pub-id pub-id-type="pmid">28666575</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0010"><string-name><surname>Narayan</surname><given-names>SM</given-names></string-name>, <string-name><surname>Franz</surname><given-names>MR</given-names></string-name>, <string-name><surname>Clopton</surname><given-names>P</given-names></string-name>, <string-name><surname>Pruvot</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Krummen</surname><given-names>DE</given-names></string-name>. <article-title>Repolarization alternans reveals vulnerability to human atrial fibrillation</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>123</volume>:<fpage>2922</fpage>–<lpage>2930</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.977827</pub-id>.<pub-id pub-id-type="pmid">21646498</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0011"><string-name><surname>Kim</surname><given-names>B‐S</given-names></string-name>, <string-name><surname>Kim</surname><given-names>Y‐H</given-names></string-name>, <string-name><surname>Hwang</surname><given-names>G‐S</given-names></string-name>, <string-name><surname>Pak</surname><given-names>H‐N</given-names></string-name>, <string-name><surname>Lee</surname><given-names>SC</given-names></string-name>, <string-name><surname>Shim</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Oh</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Ro</surname><given-names>YM</given-names></string-name>. <article-title>Action potential duration restitution kinetics in human atrial fibrillation</article-title>. <source>J Am Coll Cardiol</source>. <year>2002</year>;<volume>39</volume>:<fpage>1329</fpage>–<lpage>1336</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/S0735-1097(02)01760-6</pub-id>.<pub-id pub-id-type="pmid">11955851</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0012"><string-name><surname>Lalani</surname><given-names>GG</given-names></string-name>, <string-name><surname>Schricker</surname><given-names>AA</given-names></string-name>, <string-name><surname>Clopton</surname><given-names>P</given-names></string-name>, <string-name><surname>Krummen</surname><given-names>DE</given-names></string-name>, <string-name><surname>Narayan</surname><given-names>SM</given-names></string-name>. <article-title>Frequency analysis of atrial action potential alternans: a sensitive clinical index of individual propensity to atrial fibrillation</article-title>. <source>Circ: Arrhythm Electrophysiol</source>. <year>2013</year>;<volume>6</volume>:<fpage>859</fpage>–<lpage>867</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCEP.113.000204</pub-id>
<pub-id pub-id-type="pmid">23995250</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0013"><string-name><surname>Holmqvist</surname><given-names>F</given-names></string-name>, <string-name><surname>Platonov</surname><given-names>PG</given-names></string-name>, <string-name><surname>McNitt</surname><given-names>S</given-names></string-name>, <string-name><surname>Polonsky</surname><given-names>S</given-names></string-name>, <string-name><surname>Carlson</surname><given-names>J</given-names></string-name>, <string-name><surname>Zareba</surname><given-names>W</given-names></string-name>, <string-name><surname>Moss</surname><given-names>AJ</given-names></string-name>; <collab collab-type="authors">Investigators MI</collab>
. <article-title>Abnormal P‐wave morphology is a predictor of atrial fibrillation development and cardiac death in MADIT II patients</article-title>. <source>Ann Noninvasive Electrocardiol</source>. <year>2010</year>;<volume>15</volume>:<fpage>63</fpage>–<lpage>72</lpage>. DOI: <pub-id pub-id-type="doi">10.1111/j.1542-474X.2009.00341.x</pub-id>.<pub-id pub-id-type="pmid">20146784</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0014"><string-name><surname>Franz</surname><given-names>MR</given-names></string-name>, <string-name><surname>Jamal</surname><given-names>SM</given-names></string-name>, <string-name><surname>Narayan</surname><given-names>SM</given-names></string-name>. <article-title>The role of action potential alternans in the initiation of atrial fibrillation in humans: a review and future directions</article-title>. <source>Europace</source>. <year>2012</year>;<volume>14</volume>:<fpage>v58</fpage>–<lpage>v64</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/europace/eus273</pub-id>.<pub-id pub-id-type="pmid">23104916</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0015"><string-name><surname>Hiromoto</surname><given-names>K</given-names></string-name>, <string-name><surname>Shimizu</surname><given-names>H</given-names></string-name>, <string-name><surname>Furukawa</surname><given-names>Y</given-names></string-name>, <string-name><surname>Kanemori</surname><given-names>T</given-names></string-name>, <string-name><surname>Mine</surname><given-names>T</given-names></string-name>, <string-name><surname>Masuyama</surname><given-names>T</given-names></string-name>, <string-name><surname>Ohyanagi</surname><given-names>M</given-names></string-name>. <article-title>Discordant repolarization alternans‐induced atrial fibrillation is suppressed by verapamil</article-title>. <source>Circ J</source>. <year>2005</year>;<volume>69</volume>:<fpage>1368</fpage>–<lpage>1373</lpage>. DOI: <pub-id pub-id-type="doi">10.1253/circj.69.1368</pub-id>.<pub-id pub-id-type="pmid">16247213</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0016"><string-name><surname>Verrier</surname><given-names>RL</given-names></string-name>, <string-name><surname>Fuller</surname><given-names>H</given-names></string-name>, <string-name><surname>Justo</surname><given-names>F</given-names></string-name>, <string-name><surname>Nearing</surname><given-names>BD</given-names></string-name>, <string-name><surname>Rajamani</surname><given-names>S</given-names></string-name>, <string-name><surname>Belardinelli</surname><given-names>L</given-names></string-name>. <article-title>Unmasking atrial repolarization to assess alternans, spatiotemporal heterogeneity, and susceptibility to atrial fibrillation</article-title>. <source>Heart Rhythm</source>. <year>2016</year>;<volume>13</volume>:<fpage>953</fpage>–<lpage>961</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.hrthm.2015.11.019</pub-id>.<pub-id pub-id-type="pmid">26592850</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0017"><string-name><surname>Jousset</surname><given-names>F</given-names></string-name>, <string-name><surname>Tenkorang</surname><given-names>J</given-names></string-name>, <string-name><surname>Vesin</surname><given-names>JM</given-names></string-name>, <string-name><surname>Pascale</surname><given-names>P</given-names></string-name>, <string-name><surname>Ruchat</surname><given-names>P</given-names></string-name>, <string-name><surname>Rollin</surname><given-names>AG</given-names></string-name>, <string-name><surname>Fromer</surname><given-names>M</given-names></string-name>, <string-name><surname>Narayan</surname><given-names>SM</given-names></string-name>, <string-name><surname>Pruvot</surname><given-names>E</given-names></string-name>. <article-title>Kinetics of atrial repolarization alternans in a free‐behaving ovine model</article-title>. <source>J Cardiovasc Electrophysiol</source>. <year>2012</year>;<volume>23</volume>:<fpage>1003</fpage>–<lpage>1012</lpage>. DOI: <pub-id pub-id-type="doi">10.1111/j.1540-8167.2012.02336.x</pub-id>.<pub-id pub-id-type="pmid">22554055</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0018"><string-name><surname>Peuker</surname><given-names>ET</given-names></string-name>, <string-name><surname>Filler</surname><given-names>TJ</given-names></string-name>. <article-title>The nerve supply of the human auricle</article-title>. <source>Clin Anat</source>. <year>2002</year>;<volume>15</volume>:<fpage>35</fpage>–<lpage>37</lpage>. DOI: <pub-id pub-id-type="doi">10.1002/ca.1089</pub-id>.<pub-id pub-id-type="pmid">11835542</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0019"><string-name><surname>Merchant</surname><given-names>FM</given-names></string-name>, <string-name><surname>Armoundas</surname><given-names>AA</given-names></string-name>. <article-title>Role of substrate and triggers in the genesis of cardiac alternans, from the myocyte to the whole heart: implications for therapy</article-title>. <source>Circulation</source>. <year>2012</year>;<volume>125</volume>:<fpage>539</fpage>–<lpage>549</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.033563</pub-id>.<pub-id pub-id-type="pmid">22271847</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0020"><string-name><surname>Merchant</surname><given-names>FM</given-names></string-name>, <string-name><surname>Sayadi</surname><given-names>O</given-names></string-name>, <string-name><surname>Puppala</surname><given-names>D</given-names></string-name>, <string-name><surname>Moazzami</surname><given-names>K</given-names></string-name>, <string-name><surname>Heller</surname><given-names>V</given-names></string-name>, <string-name><surname>Armoundas</surname><given-names>AA</given-names></string-name>. <article-title>A translational approach to probe the proarrhythmic potential of cardiac alternans: a reversible overture to arrhythmogenesis?</article-title><source>Am J Physiol Heart Circ Physiol</source>. <year>2014</year>;<volume>306</volume>:<fpage>H465</fpage>–<lpage>H474</lpage>. DOI: <pub-id pub-id-type="doi">10.1152/ajpheart.00639.2013</pub-id>.<pub-id pub-id-type="pmid">24322612</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0021"><string-name><surname>Merchant</surname><given-names>FM</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>H</given-names></string-name>, <string-name><surname>Bigger</surname><given-names>T</given-names></string-name>, <string-name><surname>Steinman</surname><given-names>R</given-names></string-name>, <string-name><surname>Ikeda</surname><given-names>T</given-names></string-name>, <string-name><surname>Pedretti</surname><given-names>RF</given-names></string-name>, <string-name><surname>Salerno‐Uriarte</surname><given-names>JA</given-names></string-name>, <string-name><surname>Klersy</surname><given-names>C</given-names></string-name>, <string-name><surname>Chan</surname><given-names>PS</given-names></string-name>, <string-name><surname>Bartone</surname><given-names>C</given-names></string-name>, et al. <article-title>A combined anatomic and electrophysiologic substrate based approach for sudden cardiac death risk stratification</article-title>. <source>Am Heart J</source>. <year>2013</year>;<volume>166</volume>:<fpage>744</fpage>–<lpage>752</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.ahj.2013.06.023</pub-id>.<pub-id pub-id-type="pmid">24093856</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0022"><string-name><surname>Merchant</surname><given-names>FM</given-names></string-name>, <string-name><surname>Sayadi</surname><given-names>O</given-names></string-name>, <string-name><surname>Sohn</surname><given-names>K</given-names></string-name>, <string-name><surname>Weiss</surname><given-names>EH</given-names></string-name>, <string-name><surname>Puppala</surname><given-names>D</given-names></string-name>, <string-name><surname>Doddamani</surname><given-names>R</given-names></string-name>, <string-name><surname>Singh</surname><given-names>JP</given-names></string-name>, <string-name><surname>Heist</surname><given-names>EK</given-names></string-name>, <string-name><surname>Owen</surname><given-names>C</given-names></string-name>, <string-name><surname>Kulkarni</surname><given-names>K</given-names></string-name>, et al. <article-title>Real‐time closed‐loop suppression of repolarization alternans reduces arrhythmia susceptibility in vivo</article-title>. <source>Circ Arrhythm Electrophysiol</source>. <year>2020</year>;<volume>13</volume>:<elocation-id>e008186</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCEP.119.008186</pub-id>.<pub-id pub-id-type="pmid">32434448</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0023"><string-name><surname>Merchant</surname><given-names>FM</given-names></string-name>, <string-name><surname>Ikeda</surname><given-names>T</given-names></string-name>, <string-name><surname>Pedretti</surname><given-names>RF</given-names></string-name>, <string-name><surname>Salerno‐Uriarte</surname><given-names>JA</given-names></string-name>, <string-name><surname>Chow</surname><given-names>T</given-names></string-name>, <string-name><surname>Chan</surname><given-names>PS</given-names></string-name>, <string-name><surname>Bartone</surname><given-names>C</given-names></string-name>, <string-name><surname>Hohnloser</surname><given-names>SH</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Armoundas</surname><given-names>AA</given-names></string-name>. <article-title>Clinical utility of microvolt T‐wave alternans testing in identifying patients at high or low risk of sudden cardiac death</article-title>. <source>Heart Rhythm</source>. <year>2012</year>;<volume>9</volume>:<fpage>1256</fpage>–<lpage>1264</lpage>.e2. DOI: <pub-id pub-id-type="doi">10.1016/j.hrthm.2012.03.014</pub-id>.<pub-id pub-id-type="pmid">22406384</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0024"><string-name><surname>Merchant</surname><given-names>FM</given-names></string-name>, <string-name><surname>Salerno‐Uriarte</surname><given-names>JA</given-names></string-name>, <string-name><surname>Caravati</surname><given-names>F</given-names></string-name>, <string-name><surname>Falcone</surname><given-names>S</given-names></string-name>, <string-name><surname>Molon</surname><given-names>G</given-names></string-name>, <string-name><surname>Marangoni</surname><given-names>D</given-names></string-name>, <string-name><surname>Raczak</surname><given-names>G</given-names></string-name>, <string-name><surname>Danilowicz‐Szymanowicz</surname><given-names>L</given-names></string-name>, <string-name><surname>Pedretti</surname><given-names>RFE</given-names></string-name>, <string-name><surname>Sarzi Braga</surname><given-names>S</given-names></string-name>, et al. <article-title>Prospective use of microvolt T‐wave alternans testing to guide primary prevention implantable cardioverter defibrillator therapy</article-title>. <source>Circ J</source>. <year>2015</year>;<volume>79</volume>:<fpage>1912</fpage>–<lpage>1919</lpage>. DOI: <pub-id pub-id-type="doi">10.1253/circj.CJ-15-0253</pub-id>.<pub-id pub-id-type="pmid">26073692</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0025"><string-name><surname>Sohn</surname><given-names>K</given-names></string-name>, <string-name><surname>Dalvin</surname><given-names>SP</given-names></string-name>, <string-name><surname>Merchant</surname><given-names>FM</given-names></string-name>, <string-name><surname>Kulkarni</surname><given-names>K</given-names></string-name>, <string-name><surname>Sana</surname><given-names>F</given-names></string-name>, <string-name><surname>Abohashem</surname><given-names>S</given-names></string-name>, <string-name><surname>Singh</surname><given-names>JP</given-names></string-name>, <string-name><surname>Heist</surname><given-names>EK</given-names></string-name>, <string-name><surname>Owen</surname><given-names>C</given-names></string-name>, <string-name><surname>Isselbacher</surname><given-names>EM</given-names></string-name>, et al. <article-title>Utility of a smartphone based system (cvrPhone) to predict short‐term arrhythmia susceptibility</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>:<fpage>1</fpage>–<lpage>11</lpage>. DOI: <pub-id pub-id-type="doi">10.1038/s41598-019-50487-4</pub-id>.<pub-id pub-id-type="pmid">30626917</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0026"><string-name><surname>Smith</surname><given-names>JM</given-names></string-name>, <string-name><surname>Clancy</surname><given-names>EA</given-names></string-name>, <string-name><surname>Valeri</surname><given-names>CR</given-names></string-name>, <string-name><surname>Ruskin</surname><given-names>JN</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>RJ</given-names></string-name>. <article-title>Electrical alternans and cardiac electrical instability</article-title>. <source>Circulation</source>. <year>1988</year>;<volume>77</volume>:<fpage>110</fpage>–<lpage>121</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/01.CIR.77.1.110</pub-id>.<pub-id pub-id-type="pmid">3335062</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0027"><string-name><surname>Sayadi</surname><given-names>O</given-names></string-name>, <string-name><surname>Puppala</surname><given-names>D</given-names></string-name>, <string-name><surname>Ishaque</surname><given-names>N</given-names></string-name>, <string-name><surname>Doddamani</surname><given-names>R</given-names></string-name>, <string-name><surname>Merchant</surname><given-names>FM</given-names></string-name>, <string-name><surname>Barrett</surname><given-names>C</given-names></string-name>, <string-name><surname>Singh</surname><given-names>JP</given-names></string-name>, <string-name><surname>Heist</surname><given-names>EK</given-names></string-name>, <string-name><surname>Mela</surname><given-names>T</given-names></string-name>, <string-name><surname>Martínez</surname><given-names>JP</given-names></string-name>, et al. <article-title>A novel method to capture the onset of dynamic electrocardiographic ischemic changes and its implications to arrhythmia susceptibility</article-title>. <source>J Am Heart Assoc</source>. <year>2014</year>;<volume>3</volume>:<elocation-id>e001055</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/JAHA.114.001055</pub-id>.<pub-id pub-id-type="pmid">25187521</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0028"><string-name><surname>Goldberger</surname><given-names>AL</given-names></string-name>. <article-title>Is the normal heartbeat chaotic or homeostatic?</article-title><source>News Physiol Sci</source>. <year>1991</year>;<volume>6</volume>:<fpage>87</fpage>–<lpage>91</lpage>. DOI: <pub-id pub-id-type="doi">10.1152/physiologyonline.1991.6.2.87</pub-id>.<pub-id pub-id-type="pmid">11537649</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0029"><string-name><surname>Tsuji</surname><given-names>H</given-names></string-name>, <string-name><surname>Larson</surname><given-names>MG</given-names></string-name>, <string-name><surname>Venditti</surname><given-names>FJ</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Manders</surname><given-names>ES</given-names></string-name>, <string-name><surname>Evans</surname><given-names>JC</given-names></string-name>, <string-name><surname>Feldman</surname><given-names>CL</given-names></string-name>, <string-name><surname>Levy</surname><given-names>D</given-names></string-name>. <article-title>Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study</article-title>. <source>Circulation</source>. <year>1996</year>;<volume>94</volume>:<fpage>2850</fpage>–<lpage>2855</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/01.CIR.94.11.2850</pub-id>.<pub-id pub-id-type="pmid">8941112</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0030"><string-name><surname>De Ferrari</surname><given-names>GM</given-names></string-name>, <string-name><surname>Crijns</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Borggrefe</surname><given-names>M</given-names></string-name>, <string-name><surname>Milasinovic</surname><given-names>G</given-names></string-name>, <string-name><surname>Smid</surname><given-names>J</given-names></string-name>, <string-name><surname>Zabel</surname><given-names>M</given-names></string-name>, <string-name><surname>Gavazzi</surname><given-names>A</given-names></string-name>, <string-name><surname>Sanzo</surname><given-names>A</given-names></string-name>, <string-name><surname>Dennert</surname><given-names>R</given-names></string-name>, <string-name><surname>Kuschyk</surname><given-names>J</given-names></string-name>, et al.; <collab collab-type="authors">CardioFit Multicenter Trial I</collab>
. <article-title>Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure</article-title>. <source>Eur Heart J</source>. <year>2011</year>;<volume>32</volume>:<fpage>847</fpage>–<lpage>855</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/eurheartj/ehq391</pub-id>.<pub-id pub-id-type="pmid">21030409</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0031"><string-name><surname>Gold</surname><given-names>MR</given-names></string-name>, <string-name><surname>Van Veldhuisen</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Hauptman</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Borggrefe</surname><given-names>M</given-names></string-name>, <string-name><surname>Kubo</surname><given-names>SH</given-names></string-name>, <string-name><surname>Lieberman</surname><given-names>RA</given-names></string-name>, <string-name><surname>Milasinovic</surname><given-names>G</given-names></string-name>, <string-name><surname>Berman</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Djordjevic</surname><given-names>S</given-names></string-name>, <string-name><surname>Neelagaru</surname><given-names>S</given-names></string-name>, et al. <article-title>Vagus nerve stimulation for the treatment of heart failure: the INOVATE‐HF trial</article-title>. <source>J Am Coll Cardiol</source>. <year>2016</year>;<volume>68</volume>:<fpage>149</fpage>–<lpage>158</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jacc.2016.03.525</pub-id>.<pub-id pub-id-type="pmid">27058909</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0032"><string-name><surname>Zannad</surname><given-names>F</given-names></string-name>, <string-name><surname>De Ferrari</surname><given-names>GM</given-names></string-name>, <string-name><surname>Tuinenburg</surname><given-names>AE</given-names></string-name>, <string-name><surname>Wright</surname><given-names>D</given-names></string-name>, <string-name><surname>Brugada</surname><given-names>J</given-names></string-name>, <string-name><surname>Butter</surname><given-names>C</given-names></string-name>, <string-name><surname>Klein</surname><given-names>H</given-names></string-name>, <string-name><surname>Stolen</surname><given-names>C</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>S</given-names></string-name>, <string-name><surname>Stein</surname><given-names>KM</given-names></string-name>, et al. <article-title>Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR‐HF) randomized controlled trial</article-title>. <source>Eur Heart J</source>. <year>2015</year>;<volume>36</volume>:<fpage>425</fpage>–<lpage>433</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/eurheartj/ehu345</pub-id>.<pub-id pub-id-type="pmid">25176942</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0033"><string-name><surname>Premchand</surname><given-names>RK</given-names></string-name>, <string-name><surname>Sharma</surname><given-names>K</given-names></string-name>, <string-name><surname>Mittal</surname><given-names>S</given-names></string-name>, <string-name><surname>Monteiro</surname><given-names>R</given-names></string-name>, <string-name><surname>Dixit</surname><given-names>S</given-names></string-name>, <string-name><surname>Libbus</surname><given-names>I</given-names></string-name>, <string-name><surname>DiCarlo</surname><given-names>LA</given-names></string-name>, <string-name><surname>Ardell</surname><given-names>JL</given-names></string-name>, <string-name><surname>Rector</surname><given-names>TS</given-names></string-name>, <string-name><surname>Amurthur</surname><given-names>B</given-names></string-name>, et al. <article-title>Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM‐HF trial</article-title>. <source>J Card Fail</source>. <year>2014</year>;<volume>20</volume>:<fpage>808</fpage>–<lpage>816</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.cardfail.2014.08.009</pub-id>.<pub-id pub-id-type="pmid">25187002</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0034"><string-name><surname>Byku</surname><given-names>M</given-names></string-name>, <string-name><surname>Mann</surname><given-names>DL</given-names></string-name>. <article-title>Neuromodulation of the failing heart: lost in translation?</article-title><source>JACC Basic Transl Sci</source>. <year>2016</year>;<volume>1</volume>:<fpage>95</fpage>–<lpage>106</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jacbts.2016.03.004</pub-id>.<pub-id pub-id-type="pmid">27525317</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0035"><string-name><surname>Frangos</surname><given-names>E</given-names></string-name>, <string-name><surname>Ellrich</surname><given-names>J</given-names></string-name>, <string-name><surname>Komisaruk</surname><given-names>BR</given-names></string-name>. <article-title>Non‐invasive access to the vagus nerve central projections via electrical stimulation of the external ear: fMRI evidence in humans</article-title>. <source>Brain Stimul</source>. <year>2015</year>;<volume>8</volume>:<fpage>624</fpage>–<lpage>636</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.brs.2014.11.018</pub-id>.<pub-id pub-id-type="pmid">25573069</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0036"><string-name><surname>Qin</surname><given-names>D</given-names></string-name>, <string-name><surname>Singh</surname><given-names>JP</given-names></string-name>. <article-title>Low‐level tragus stimulation for atrial fibrillation: a glimpse of hope for neuromodulation?</article-title><source>JACC Clin Electrophysiol</source>. <year>2020</year>;<volume>6</volume>:<fpage>292</fpage>–<lpage>294</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jacep.2020.01.003</pub-id>.<pub-id pub-id-type="pmid">32192679</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0037"><string-name><surname>Stavrakis</surname><given-names>S</given-names></string-name>, <string-name><surname>Kulkarni</surname><given-names>K</given-names></string-name>, <string-name><surname>Singh</surname><given-names>JP</given-names></string-name>, <string-name><surname>Katritsis</surname><given-names>DG</given-names></string-name>, <string-name><surname>Armoundas</surname><given-names>AA</given-names></string-name>. <article-title>Autonomic modulation of cardiac arrhythmias: methods to assess treatment and outcomes</article-title>. <source>JACC Clin Electrophysiol</source>. <year>2020</year>;<volume>6</volume>:<fpage>467</fpage>–<lpage>483</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jacep.2020.02.014</pub-id>.<pub-id pub-id-type="pmid">32439031</pub-id></mixed-citation>
              </ref>
              <ref id="jah36326-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="jah36326-cit-0038"><string-name><surname>Ardell</surname><given-names>JL</given-names></string-name>, <string-name><surname>Nier</surname><given-names>H</given-names></string-name>, <string-name><surname>Hammer</surname><given-names>M</given-names></string-name>, <string-name><surname>Southerland</surname><given-names>EM</given-names></string-name>, <string-name><surname>Ardell</surname><given-names>CL</given-names></string-name>, <string-name><surname>Beaumont</surname><given-names>E</given-names></string-name>, <string-name><surname>KenKnight</surname><given-names>BH</given-names></string-name>, <string-name><surname>Armour</surname><given-names>JA</given-names></string-name>. <article-title>Defining the neural fulcrum for chronic vagus nerve stimulation: implications for integrated cardiac control</article-title>. <source>J Physiol</source>. <year>2017</year>;<volume>595</volume>:<fpage>6887</fpage>–<lpage>6903</lpage>. DOI: <pub-id pub-id-type="doi">10.1113/JP274678</pub-id>.<pub-id pub-id-type="pmid">28862330</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
